Sangamo Therapeutics, Inc.

Sangamo Therapeutics is a genomic medicine company whose research and development pipeline relies on animal testing. The company’s public disclosures and scientific literature reference the use of transgenic animals and large animal models as integral to its preclinical work. For example, its clinical trial for SB-525/PF-0755480 (NCT03061201), developed in collaboration with Pfizer, followed dosing proven effective in animal studies. Recent company presentations, such as an April 2025 session on translational approaches for neurological diseases, specifically highlight work in large animal models. As a biotechnology firm advancing gene therapies, Sangamo’s regulatory submissions and development process inherently require animal testing to demonstrate safety and efficacy before proceeding to human trials. This places the company within the scope of the animal testing exclusion for its direct and necessary use of animals in product development.